New Real-Time Reverse Transcriptase-Initiated PCR Assay with Single-Copy Sensitivity for Human Immunodeficiency Virus Type 1 RNA in Plasma

ABSTRACT More sensitive assays for human immunodeficiency virus type 1 (HIV-1) RNA are needed to detect, quantify, and characterize persistent viremia in patients who are receiving antiretroviral therapy and whose plasma HIV-1 RNA levels are suppressed to less than 50 to 75 copies/ml. We therefore developed an internally controlled real-time reverse transcriptase-initiated PCR assay that quantifies HIV-1 RNA concentrations down to 1 copy per ml of plasma. This assay with single-copy sensitivity (the single-copy assay) generates a reproducible linear regression plot of input copy number versus threshold cycle by using HIV-1 RNA transcripts at copy numbers ranging from 1 to 106 per reaction mixture. The single-copy assay was compared to the ultrasensitive AMPLICOR HIV-1 MONITOR assay and a more sensitive modification of the ultrasensitive assay by repeatedly testing a low-copy-number panel containing 200 to 0.781 copies of HIV-1 RNA per ml of plasma. This comparison showed that the single-copy assay had a greater sensitivity than the other assays and was the only assay that detected HIV-1 RNA at levels as low as 0.781 copies/ml. Testing of plasma samples from 15 patients who were receiving antiretroviral therapy and who had <75 HIV-1 RNA copies/ml revealed persistent viremia in all 15 patients, with HIV-1 RNA levels ranging from 1 to 32 copies/ml (median, 13 copies/ml). The greater sensitivity of the single-copy assay should allow better characterization of persistent viremia in patients who are receiving antiretroviral therapy and whose HIV-1 RNA levels are suppressed to below the detection limits of present assays.

[1]  P. Hartigan,et al.  Changes in Plasma HIV RNA Levels and CD4+ Lymphocyte Counts Predict Both Response to Antiretroviral Therapy and Therapeutic Failure , 1997, Annals of Internal Medicine.

[2]  K. Livak,et al.  Oligonucleotides with fluorescent dyes at opposite ends provide a quenched probe system useful for detecting PCR product and nucleic acid hybridization. , 1995, PCR methods and applications.

[3]  M. Hirsch,et al.  Prevalence and predictive value of intermittent viremia with combination hiv therapy. , 2001, JAMA.

[4]  D. Richman,et al.  Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. , 1997, Science.

[5]  D. Ho,et al.  Use of Real-Time PCR and Molecular Beacons To Detect Virus Replication in Human Immunodeficiency Virus Type 1-Infected Individuals on Prolonged Effective Antiretroviral Therapy , 1999, Journal of Virology.

[6]  J. Lifson,et al.  Quantitative competitive polymerase chain reaction for accurate quantitation of HIV DNA and RNA species. , 1993, BioTechniques.

[7]  M A Nowak,et al.  Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[8]  A. Fauci,et al.  The immunopathogenesis of human immunodeficiency virus infection. , 1993, The New England journal of medicine.

[9]  R Brookmeyer,et al.  Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. , 1997, Science.

[10]  S. Hughes,et al.  The EV-O-derived cell line DF-1 supports the efficient replication of avian leukosis-sarcoma viruses and vectors. , 1998, Virology.

[11]  S. J. Clark,et al.  Determination of plasma viral load in HIV‐1 infection by quantitative competitive polymerase chain reaction , 1993, AIDS.

[12]  J Kolberg,et al.  A branched DNA signal amplification assay for quantification of nucleic acid targets below 100 molecules/ml. , 1997, Nucleic acids research.

[13]  J. Levy Pathogenesis of human immunodeficiency virus infection , 1989, Microbiological reviews.

[14]  D. Brambilla,et al.  Ultrasensitive Reverse Transcription-PCR Assay for Quantitation of Human Immunodeficiency Virus Type 1 RNA in Plasma , 1998, Journal of Clinical Microbiology.

[15]  John W. Mellors,et al.  Prognosis in HIV-1 Infection Predicted by the Quantity of Virus in Plasma , 1996, Science.

[16]  B. Korber,et al.  HIV sequence compendium 2002 , 2002 .

[17]  Julio S. G. Montaner,et al.  Suppression of plasma viral load below 20 copies/ml is required to achieve a long‐term response to therapy , 1998, AIDS.

[18]  S. Yerly,et al.  CONCISE COMMUNICATIONS Cell-Associated HIV-1 RNA in Blood as Indicator of Virus Load in Lymph Nodes , 1999 .

[19]  C. Crumpacker,et al.  Detection of human immunodeficiency virus type 1 clinical isolates with reduced sensitivity to zidovudine and dideoxyinosine by RNA.RNA hybridization. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[20]  J. Sninsky,et al.  Rapid and simple PCR assay for quantitation of human immunodeficiency virus type 1 RNA in plasma: application to acute retroviral infection , 1994, Journal of clinical microbiology.

[21]  R. Pomerantz,et al.  Residual HIV-1 RNA in blood plasma of patients taking suppressive highly active antiretroviral therapy. , 2001, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[22]  M. Hughes,et al.  Monitoring Plasma HIV-1 RNA Levels in Addition to CD4+ Lymphocyte Count Improves Assessment of Antiretroviral Therapeutic Response , 1997, Annals of Internal Medicine.

[23]  A. Perelson,et al.  Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection , 1995, Nature.

[24]  Roger Detels,et al.  Plasma Viral Load and CD4+ Lymphocytes as Prognostic Markers of HIV-1 Infection , 1997, Annals of Internal Medicine.

[25]  S. Hughes,et al.  Adaptor plasmids simplify the insertion of foreign DNA into helper-independent retroviral vectors , 1987, Journal of virology.

[26]  S D Kemp,et al.  Multiple mutations in HIV-1 reverse transcriptase confer high-level resistance to zidovudine (AZT). , 1989, Science.

[27]  P. Harrigan,et al.  Rebound of plasma HIV viral load following prolonged suppression with combination therapy. , 1998, AIDS.

[28]  F. Hecht,et al.  Quantitative and Cost Comparison of Ultrasensitive Human Immunodeficiency Virus Type 1 RNA Viral Load Assays: Bayer bDNA Quantiplex Versions 3.0 and 2.0 and Roche PCR Amplicor Monitor Version 1.5 , 2000, Journal of Clinical Microbiology.

[29]  T. Merigan,et al.  Multiple Concurrent Reverse Transcriptase and Protease Mutations and Multidrug Resistance of HIV-1 Isolates from Heavily Treated Patients , 1998, Annals of Internal Medicine.

[30]  J. Coffin,et al.  HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy , 1995, Science.